Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment.
Gergely TG, Kucsera D, Tóth VE, Kovács T, Sayour NV, Drobni ZD, Ruppert M, Petrovich B, Ágg B, Onódi Z, Fekete N, Pállinger É, Buzás EI, Yousif LI, Meijers WC, Radovits T, Merkely B, Ferdinandy P, Varga ZV.
Gergely TG, et al. Among authors: fekete n.
Br J Pharmacol. 2023 Mar;180(6):740-761. doi: 10.1111/bph.15984. Epub 2022 Dec 13.
Br J Pharmacol. 2023.
PMID: 36356191
Free article.